A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future

References

• Zyprexa [package Insert]. Indianapolis (IN): Eli Lilly and Company; 2018.
   Google Scholar
• Zyprexa (Olanzapine) new drug approval package. 1996. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/020592_Original_Approval_Pkg%20.pdf. Accessed September 26, 2018.
   Google Scholar
• Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;3:CD006654.
   Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51–68.
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry. 2001;62(10):757–771.
   Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553–564. doi:10.1001/archpsyc.60.6.553
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71–93. doi:10.1093/schbul/sbp116
   PubMed Web of Science ®Google Scholar
• Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013;21(1):18–40. doi:10.1097/HRP.0b013e31827fd915
   PubMed Web of Science ®Google Scholar
• Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–472. doi:10.1177/0004867416641195
   PubMed Web of Science ®Google Scholar
• Keating D, McWilliams S, Schneider I, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881. doi:10.1136/bmjopen-2016-013881
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd ed; 2010. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf. Accessed January 28, 2019.
   Google Scholar
• Agid O, Foussias G, Singh S, Remington G. Where to position clozapine: re-examining the evidence. Can J Psychiatry. 2010;55(10):677–684. doi:10.1177/070674371005501007
   PubMed Web of Science ®Google Scholar
• Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009;9(7):1045–1058. doi:10.1586/ern.09.54
   PubMed Web of Science ®Google Scholar
• Society for Medicines Research. Case histories of drug discovery. 1999. Available from: https://www.smr.org.uk/smr/archive/pastmeetings/Downloads/19991202.pdf. Accessed September 26, 2018.
   Google Scholar
• Shen WW. The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry. 1999;11(3):145–158.
   Google Scholar
• Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96. doi:10.1016/0893-133X(94)00129-N
   PubMed Web of Science ®Google Scholar
• Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol. 1992;77(1):87–93.
   Google Scholar
• Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther. 1992;262(2):545–551.
   PubMed Web of Science ®Google Scholar
• Pan B, Lian J, Deng C. Chronic antipsychotic treatment differentially modulates protein kinase A- and glycogen synthase kinase 3 beta-dependent signaling pathways, N-methyl-D-aspartate receptor and gamma-aminobutyric acid A receptors in nucleus accumbens of juvenile rats. J Psychopharmacol (Oxford). 2018;32(11):1252–1263. doi:10.1177/0269881118788822
   PubMed Web of Science ®Google Scholar
• Krzystanek M, Bogus K, Palasz A, Krzystanek E, Worthington JJ, Wiaderkiewicz R. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacol Rep. 2015;67(5):965–969. doi:10.1016/j.pharep.2015.01.017
   Web of Science ®Google Scholar
• Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol. 1995;10(4):239–244.
   Web of Science ®Google Scholar
• Zyprexa [orginial Package Insert]. Indianapolis (IN): Eli Lilly and Company; 1996.
   Google Scholar
• Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005;(2):CD001359.
   Web of Science ®Google Scholar
• Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97. doi:10.1016/S0140-6736(15)01121-6
   PubMed Web of Science ®Google Scholar
• Juckel G, de Bartolomeis A, Gorwood P, et al. Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatr Dis Treat. 2014;10:1867–1878. doi:10.2147/NDT.S61672
   PubMed Web of Science ®Google Scholar
• Correll CU, Kishimoto T, Nielsen J, Kane JM. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12):B16–39. doi:10.1016/j.clinthera.2011.11.016
   PubMed Web of Science ®Google Scholar
• Kumari S, Malik M, Florival C, Manalai P, Sonje S. An assessment of five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used symptoms rating scales in schizophrenia and comparison to newer scales (CAINS, BNSS). J Addict Res Ther. 2017;8(3). doi:10.4172/2155-6105.1000324
   Google Scholar
• Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl. 2007;50:s7–s14. doi:10.1192/bjp.191.50.s7
   PubMedGoogle Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37.
   PubMedGoogle Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10(3):799–812. doi:10.2466/pr0.1962.10.3.799
   Web of Science ®Google Scholar
• Haro JM, Kamath SA, Ochoa S, et al. The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003;(416):16–23. doi:10.1034/j.1600-0447.107.s416.5.x
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917–1928. doi:10.1517/14656560903061309
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962. doi:10.1016/S0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Liu-Seifert H, Adams DH, Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol. 2006;26(6):632–637. doi:10.1097/01.jcp.0000245563.06660.0f
   Web of Science ®Google Scholar
• Volavka J, Czobor P, Citrome L, Van Dorn RA. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. 2014;19(5):374–381. doi:10.1017/S1092852913000849
   Web of Science ®Google Scholar
• Volavka J, Czobor P, Derks EM, et al. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2011;72(7):955–961. doi:10.4088/JCP.10m06529
   PubMed Web of Science ®Google Scholar
• Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr., Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry. 1999;156(1):79–87. doi:10.1176/ajp.156.1.79
   PubMed Web of Science ®Google Scholar
• Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86(1–3):234–243. doi:10.1016/j.schres.2006.06.021
   Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097. doi:10.1016/S0140-6736(08)60486-9
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060. doi:10.1176/ajp.2007.164.7.1050
   PubMed Web of Science ®Google Scholar
• Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int J Clin Pract. 2008;62(5):837–840. doi:10.1111/j.1742-1241.2008.01758.x
   Web of Science ®Google Scholar
• Beasley CM Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124(1–2):159–167. doi:10.1007/bf02245617
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr., Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111–123. doi:10.1016/0893-133X(95)00069-P
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr., Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7(2):125–137.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM Jr., Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154(4):457–465. doi:10.1176/ajp.154.4.457
   PubMed Web of Science ®Google Scholar
• Svestka J, Synek O, Zourkova A. A double-blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders [abstract P.2.031]. Eur Neuropsychopharmacol. 2003;13(4):S292. doi:10.1016/S0924-977X(03)91984-5
   Web of Science ®Google Scholar
• Riedel M, Muller N, Spellmann I, et al. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2007;257(7):402–412. doi:10.1007/s00406-007-0748-9
   PubMed Web of Science ®Google Scholar
• Grootens KP, van Veelen NM, Peuskens J, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37(2):352–361. doi:10.1093/schbul/sbp037
   Web of Science ®Google Scholar
• McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(suppl 18):47–56.
   PubMed Web of Science ®Google Scholar
• Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2006;63(6):622–629. doi:10.1001/archpsyc.63.6.622
   PubMed Web of Science ®Google Scholar
• He H, Zhou Y, Yang M, Li X, Xiang YT, Luo J. Comparison of olanzapine versus other second-generation antipsychotics in the improvement of insight and medication discontinuation rate in schizophrenia. Shanghai Arch Psychiatry. 2018;30(3):178–187. doi:10.11919/j.issn.1002-0829.217087
   Google Scholar
• Smith TE, Weston CA, Lieberman JA. Schizophrenia (maintenance treatment). BMJ Clin Evid. 2009;2009:1007.
   Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16(7):473–484. doi:10.2165/00023210-200216070-00004
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449. doi:10.1176/appi.ajp.162.3.441
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. doi:10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• Levitan B, Markowitz M, Mohamed AF, et al. Patients’ preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatr Serv. 2015;66(7):719–726. doi:10.1176/appi.ps.201400188
   PubMed Web of Science ®Google Scholar
• Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998;172:499–505. doi:10.1192/bjp.172.6.499
   PubMed Web of Science ®Google Scholar
• Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235–244. doi:10.1016/j.euroneuro.2006.09.005
   Web of Science ®Google Scholar
• Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res. 2011;133(1–3):42–46. doi:10.1016/j.schres.2011.09.018
   Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006;26(6):571–578. doi:10.1097/01.jcp.0000246215.49271.b8
   PubMed Web of Science ®Google Scholar
• Markowitz MA, Levitan BS, Mohamed AF, et al. Psychiatrists’ judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment. Psychiatr Serv. 2014;65(9):1133–1139. doi:10.1176/appi.ps.201300290
   PubMed Web of Science ®Google Scholar
• Khin NA, Chen YF, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry. 2012;73(6):856–864. doi:10.4088/JCP.11r07539
   PubMed Web of Science ®Google Scholar
• Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry. 2001;1:7. doi:10.1186/1471-244X-1-7
   PubMed Web of Science ®Google Scholar
• Weiden PJ. How many treatments before clozapine? medication choices across the spectrum of treatment resistance in schizophrenia. J Clin Psychiatry. 2016;77(5):e594–e596. doi:10.4088/JCP.16com10797
   Web of Science ®Google Scholar
• Schooler NR, Marder SR, Chengappa KN, et al. Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. J Clin Psychiatry. 2016;77(5):628–634. doi:10.4088/JCP.13m08351
   PubMed Web of Science ®Google Scholar
• Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63–76. doi:10.1097/YIC.0b013e32836508e6
   PubMed Web of Science ®Google Scholar
• Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry. 1999;45(4):403–411. doi:10.1016/s0006-3223(98)00291-1
   PubMed Web of Science ®Google Scholar
• Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255–262. doi:10.1176/appi.ajp.159.2.255
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610. doi:10.1176/appi.ajp.163.4.600
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Birkett MA, Kiesler GM, Wood AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49(1):52–63. doi:10.1016/s0006-3223(00)01026-x
   PubMed Web of Science ®Google Scholar
• Bitter I, Dossenbach MR, Brook S, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):173–180. doi:10.1016/j.pnpbp.2003.09.033
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Roy A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008;69(2):274–285.
   PubMed Web of Science ®Google Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199–210. doi:10.1001/jamapsychiatry.2015.2955
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392–400. doi:10.1097/JCP.0b013e31817e63a5
   PubMed Web of Science ®Google Scholar
• Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf. 2008;7(6):761–769. doi:10.1517/14740330802423234
   PubMed Web of Science ®Google Scholar
• Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455–482. doi:10.2165/11589060-000000000-00000
   PubMed Web of Science ®Google Scholar
• Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs. 2005;65(8):1113–1138. doi:10.2165/00003495-200565080-00006
   Web of Science ®Google Scholar
• Czekalla J, Kollack-Walker S, Beasley CM Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry. 2001;62(suppl 2):35–40.
   Google Scholar
• De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–126. doi:10.1038/nrendo.2011.156
   Web of Science ®Google Scholar
• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267–272.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119(1):4–14. doi:10.1111/j.1600-0447.2008.01317.x
   PubMed Web of Science ®Google Scholar
• Chen CH, Shyue SK, Hsu CP, Lee TS. Atypical antipsychotic drug olanzapine deregulates hepatic lipid metabolism and aortic inflammation and aggravates atherosclerosis. Cell Physiol Biochem. 2018;50(4):1216–1229. doi:10.1159/000494573
   Google Scholar
• Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010;10(7):1175–1200. doi:10.1586/ern.10.85
   PubMed Web of Science ®Google Scholar
• Smith RC, Maayan L, Wu R, et al. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2018;235(12):3545–3558. doi:10.1007/s00213-018-5079-1
   PubMed Web of Science ®Google Scholar
• Barak N, Beck Y, Albeck JH. Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol (Oxford). 2016;30(3):237–241. doi:10.1177/0269881115626349
   PubMed Web of Science ®Google Scholar
• Lian J, Huang XF, Pai N, Deng C. Ameliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implications. Pharmacol Res. 2016;106:51–63. doi:10.1016/j.phrs.2016.02.011
   PubMed Web of Science ®Google Scholar
• Lian J, Huang XF, Pai N, Deng C. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment. PLoS One. 2014;9(8):e104160. doi:10.1371/journal.pone.0104160
   Web of Science ®Google Scholar
• Citrome L. Olanzapine: interpreting the label change. Int J Clin Pract. 2007;61(12):1960–1962. doi:10.1111/j.1742-1241.2007.01631.x
   Web of Science ®Google Scholar
• Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241. doi:10.2147/NDT.S113099
   PubMed Web of Science ®Google Scholar
• de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16(1):341. doi:10.1186/s12888-016-1049-5
   PubMed Web of Science ®Google Scholar
• Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci. 2015;9:297. doi:10.3389/fnins.2015.00297
   PubMed Web of Science ®Google Scholar
• Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr., Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry. 1997;58(5):205–211.
   Web of Science ®Google Scholar
• Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry. 2003;64(8):898–906.
   Web of Science ®Google Scholar
• Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121–1128.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Rapini G, Olivieri L, et al. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf. 2018;9(5):237–256. doi:10.1177/2042098618756261
   PubMed Web of Science ®Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17(5):407–418.
   PubMed Web of Science ®Google Scholar
• Chen YL, Cheng TS, Lung FW. Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Prim Care Companion J Clin Psychiatry. 2009;11(1):16–20. doi:10.4088/pcc.08m00668
   Google Scholar
• Costa AM, de Lima MS, Faria M, Filho SR, de Oliveira IR, de Jesus Mari J. A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol (Oxford). 2007;21(2):165–170. doi:10.1177/0269881107066333
   Web of Science ®Google Scholar
• Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31(5):577–588. doi:10.1016/j.psyneuen.2005.12.006
   PubMed Web of Science ®Google Scholar
• Tewksbury A, Olander A. Management of antipsychotic-induced hyperprolactinemia. Ment Health Clin. 2016;6(4):185–190. doi:10.9740/mhc.2016.07.185
   PubMedGoogle Scholar
• Epilepsy Foundation. Antipsychotics. 2019. Available from: https://www.epilepsy.com/learn/professionals/diagnosis-treatment/psychotropic-drugs-developmental-disabilities/comorbid-5. Accessed July 17, 2019.
   Google Scholar